Based on the siRNA findings, we evaluated the therapeutic efficacy of dinaciclib, a pan CDK inhibitor that exhibits the highest affinity for CDK1/2, in combination with the CDK4/6i palbociclib and ET in the AI-resistant BC cell models. Here, CDK1 is linked to breast cancer.